{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:10:33Z","timestamp":1794967833621,"version":"4.9.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jpsychires.2021.03.002","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T03:02:07Z","timestamp":1615086127000},"page":"273-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review"],"prefix":"10.1016","volume":"137","author":[{"given":"Bruno","family":"Romeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-4512","authenticated-orcid":false,"given":"Marianne","family":"Hermand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"P\u00e9tillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Karila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Benyamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2021.03.002_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/2045125314527985","article-title":"Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles","volume":"4","author":"Baumeister","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib3","doi-asserted-by":"crossref","first-page":"12138","DOI":"10.1523\/JNEUROSCI.3245-10.2010","article-title":"Enhanced function of prefrontal serotonin 5-HT2 receptors in a rat model of psychiatric vulnerability","volume":"30","author":"Benekareddy","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00213-017-4701-y","article-title":"Psychedelics and connectedness","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib8","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib9","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jad.2018.01.006","article-title":"Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression","volume":"230","author":"Carrillo","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4331\/wjbc.v4.i4.141","article-title":"Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion","volume":"4","author":"Castro-Neto","year":"2013","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1556\/2054.01.2017.009","article-title":"Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning","volume":"1","author":"Davis","year":"2017","journal-title":"J. Psychedelic Stud."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fpsyg.2019.01234","article-title":"Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial","volume":"10","author":"de Almeida","year":"2019","journal-title":"Front. Psychol."},{"issue":"iii\u2013x","key":"10.1016\/j.jpsychires.2021.03.002_bib14","first-page":"1","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technol. Assess. Winch. Engl."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib15","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1038\/npp.2016.82","article-title":"LSD acutely impairs fear recognition and enhances emotional empathy and sociality","volume":"41","author":"Dolder","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/acps.12904","article-title":"Effects of psilocybin therapy on personality structure","volume":"138","author":"Erritzoe","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int. Rev. Psychiatr. Abingdon Engl."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey","volume":"10","author":"Garcia-Romeu","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Garcia-Romeu","year":"2019","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","article-title":"Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions","volume":"30","author":"Garcia-Romeu","year":"2018","journal-title":"Int. Rev. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jad.2017.05.048","article-title":"Emotional blunting with antidepressant treatments: a survey among depressed patients","volume":"221","author":"Goodwin","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archpsyc.64.3.356","article-title":"Serotonin receptor 2A gene and the influence of childhood maternal nurturance on adulthood depressive symptoms","volume":"64","author":"Jokela","year":"2007","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib34","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nicl.2015.08.009","article-title":"The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity","volume":"11","author":"Kraehenmann","year":"2016","journal-title":"Neuroimage-Clin."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.05.031","article-title":"Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990\u20132014: a systematic review and meta-analysis","volume":"154","author":"Lai","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022799","article-title":"Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development","volume":"6","author":"Lambe","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib39","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bdi.12003","article-title":"Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression","volume":"14","author":"Luckenbaugh","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib40","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib41","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0269881119895520","article-title":"Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression","volume":"34","author":"Mertens","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib43","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1524-4733.2003.00242.x","article-title":"A checklist for retrospective database studies\u2014report of the ISPOR task force on retrospective databases","volume":"6","author":"Motheral","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.54","article-title":"Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects","volume":"7","author":"Mueller","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0166-4328(02)00311-X","article-title":"Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety","volume":"140","author":"Nic Dhonnchadha","year":"2003","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0166-4328(03)00179-7","article-title":"Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice","volume":"147","author":"Nic Dhonnchadha","year":"2003","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib49","article-title":"Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder","volume":"18","author":"Niciu","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib50","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","article-title":"Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"65","author":"Phelps","year":"2009","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib52","article-title":"Developing guidelines and competencies for the training of psychedelic therapists","volume":"29","author":"Phelps","year":"2017","journal-title":"J. Hum. Psy. June"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib53","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1073\/pnas.1524187113","article-title":"Effects of serotonin 2A\/1A receptor stimulation on social exclusion processing","volume":"113","author":"Preller","year":"2016","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib54","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.encep.2016.06.005","article-title":"Facteurs pr\u00e9dictifs de la r\u00e9ponse antid\u00e9pressive \u00e0 la k\u00e9tamine dans les \u00e9pisodes d\u00e9pressifs majeurs r\u00e9sistants: revue de la litt\u00e9rature","volume":"43","author":"Romeo","year":"2017","journal-title":"L\u2019Enc\u00e9phale"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression","volume":"142","author":"Roseman","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib56","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib57","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib58","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/acer.13522","article-title":"Impact of social cognition on alcohol dependence treatment outcome: poorer facial emotion recognition predicts relapse\/dropout","volume":"41","author":"Rupp","year":"2017","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib59","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00213-019-05279-z","article-title":"Replication and extension of a model predicting response to psilocybin","volume":"236","author":"Russ","year":"2019","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1248\/bpb.b14-00315","article-title":"Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats","volume":"38","author":"Sakashita","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(12)60600-X","article-title":"Shaping the renaissance of psychedelic research","volume":"380","author":"Sessa","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib62","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1192\/bjp.186.6.457","article-title":"Can psychedelics have a role in psychiatry once again?","volume":"186","author":"Sessa","year":"2005","journal-title":"Br. J. Psychiatr. J. Ment. Sci."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroimage.2019.04.009","article-title":"Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects","volume":"196","author":"Smigielski","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib64","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","article-title":"Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression","volume":"235","author":"Stroud","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","article-title":"Psychedelic-Assisted group therapy: a systematic review","volume":"51","author":"Trope","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib66","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","article-title":"5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man\u2014a PET study with [11C]raclopride","volume":"20","author":"Vollenweider","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2021.03.002_bib67","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"OPINION the neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib68","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients' accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.jpsychires.2021.03.002_bib69","article-title":"Reduced brain resting-state network specificity in infants compared with adults","volume":"1349","author":"Wylie","year":"2014","journal-title":"Neuropsychiatric Dis. Treat."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239562100145X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002239562100145X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:21:43Z","timestamp":1758367303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002239562100145X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":68,"alternative-id":["S002239562100145X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.03.002","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}